Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Oncological Outcomes and Long-Term Survival among Patients with Gastric Cancer and Limited Peritoneal Disease Progression after Neoadjuvant Chemotherapy.
Sebastian KobiałkaKatarzyna SędłakZuzanna PelcRadosław MlakYutaka EndoPaweł BogaczAndrzej KurylcioWojciech P PolkowskiTimothy M PawlikKarol Rawicz-PruszyńskiPublished in: Journal of clinical medicine (2023)
Data from the current study demonstrated a lack of survival benefit among advanced GC patients with PM undergoing gastrectomy with CRS+HIPEC when compared with individuals after gastrectomy with CRS alone. Administration of perioperative chemotherapy and achievement of TO failed to withstand the peritoneal disease progression during NAC.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- rectal cancer
- squamous cell carcinoma
- radiation therapy
- sentinel lymph node
- lymph node
- air pollution
- transcription factor
- patients undergoing
- heavy metals
- electronic health record
- prostate cancer
- radical prostatectomy
- type diabetes
- skeletal muscle
- adipose tissue
- risk assessment
- artificial intelligence
- polycyclic aromatic hydrocarbons
- free survival
- insulin resistance
- data analysis
- simultaneous determination
- genome wide analysis